UC Davis Comprehensive Cancer Center | Strategic Alliance Partners

January 10, 2024

R. Lor Randall, MD, FACS, emphasizes the overall potential for investigating the utility of engineered bone marrow in patients with osteosarcoma.

December 21, 2023

New research led by a UC Davis Comprehensive Cancer Center clinical scientist shows blood tests used to hunt for cancer DNA may help detect cancers faster and guide the use of targeted therapies.

October 03, 2023

UC Davis Comprehensive Cancer Center has launched the state’s first-ever Tobacco Cessation Policy Research Center.

September 12, 2023

R. Lor Randall, MD, FACS, discusses the process of organizing the symposium, key surgical and non-surgical advancements as well as socioeconomic disparities identified in these papers, and the importance of this information for both surgical and medical oncologists.

August 29, 2023

Gene therapy that induces the body to create microRNA-22, a naturally occurring molecule, successfully treated mice with hepatocellular carcinoma, the most common form of liver cancer.

August 16, 2023

R. Lor Randall, MD, FACS, explains the difference between noncancerous chondroblastoma and other bone neoplasms, details the typical diagnosis and treatment of this rare condition, and emphasizes the importance of pediatric and medical oncologists being able to identify it in clinic.

August 04, 2023

R. Lor Randall, MD, FACS, provides details about the 2024 Birmingham Orthopedic Oncology Meeting and its main topic of discussion, explains the rationale for its inception, and emphasizes the importance of this meeting for orthopedic oncologists treating chondrosarcoma.

June 20, 2023

R. Lor Randall, MD, FACS, discusses the use of neoadjuvant pazopanib in patients with non-rhabdomyosarcoma soft tissue sarcoma, expanded on findings from the subgroup analysis of ARST1321, and detailed the implications of these findings.

June 14, 2023

R. Lor Randall, MD, FACS, discusses findings from a study of one-stage synovectomy in patients with diffuse-type tenosynovial giant cell tumor of the knee.

June 14, 2023

R. Lor Randall, MD, FACS, discusses the standard treatment approach for patients with diffuse-type tenosynovial giant cell tumor, the results of the retrospective cohort study evaluating 1- vs 2-stage synovectomies in these patients, and the importance of having additional treatment options for this patient population.

May 29, 2023

New study led by UC Davis Comprehensive Cancer Center could improve outcomes for common cancer found in 1 in 8 men.

May 18, 2023

Closing out their discussion on urothelial carcinoma, key opinion leaders share clinical pearls and excitement for the evolving treatment landscape.

May 18, 2023

A brief review of second-line and subsequent treatment strategies in metastatic urothelial carcinoma and novel therapies being explored in this space.

May 11, 2023

Shared insight on clinical trial data behind the intensification of maintenance immunotherapy in patients with metastatic urothelial carcinoma.

May 11, 2023

Centering discussion on several key clinical trials, expert panelists reflect on data behind maintenance avelumab in metastatic urothelial carcinoma.

May 04, 2023

A panel of four key opinion leaders discuss the role of maintenance therapy in metastatic urothelial carcinoma and how its use has impacted the treatment landscape.

May 04, 2023

A brief review of the appropriate number of chemotherapy cycles to utilize in the setting of metastatic urothelial carcinoma.

April 27, 2023

Switching their focus to the metastatic urothelial carcinoma treatment landscape, panelists identify cornerstone frontline treatment options.

April 27, 2023

A comprehensive review of novel treatment strategies in MIBC, including perioperative therapy, and respective ongoing clinical trials.

April 20, 2023

Expert panelists reflect on the molecular subtyping of patients to predict response to neoadjuvant therapy in Bladder BRIDGister.